Cempra To Defend CABP Antibiotic's Safety At US FDA Advisory Panel
Solithera's efficacy profile appears strong, but FDA has safety concerns, particularly its structural similarities to the controversial Ketek.
You may also be interested in...
Cempra's Solithera Draws FDA Complete Response Letter On Liver Risks
Limited population approval pathway in 21st Century Cures law may not help Cempra overcome US agency's request for new 9,000-patient safety study of the macrolide antibiotic.
Advisory Committee Recommendations Could Limit Use Of Solithera
Panelists recommended stringent labeling for Cempra's proposed antibiotic for community-acquired bacterial pneumonia, which could ultimately limit utilization of the drug over concerns about possible liver damage.
Cempra’s Antibiotic Likely Needs Bigger Trial – But Might Be Able To Do It In Phase IV
FDA advisory committee votes 7-6 that the strong efficacy profile of Solithera (solithromycin) outweighs its unknown safety risks; panels agreed that more data was needed, but were split on whether it was needed pre- or post-approval.